<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">
Nasarawa State University, KeffiNasarawa State University, KeffiInstitutional Repository

IN-SILICO STRUCTURE-ACTIVITY RELATIONSHIP AND MOLECULAR DOCKING STUDY OF NEROLIDOL AND ITS MODIFIED ANALOGUE AGAINST THE TRYPANOSOMABRUCEIHEXOKINASE

Abstract

Trypanosoma brucei is a species of parasitic kinetoplastid belonging to the genus Trypanosoma. The parasite is the cause of a vector-borne disease of vertebrate animals, including humans, carried by genera of tsetse fly in sub-Saharan Africa. In humans T. brucei causes African trypanosomiasis, or sleeping sickness. Nerolidol is a terpene that is also known as peruviol. It is found in a number of plants, including cannabis sativa. Nerolidol has two isomers and is a sesquiterpene, which means it is more stable than other terpenes. Molecular docking study was carried out on nerolidol and its modified analogue against Trypanosoma brucei hexokinase using the Autodock Vina software. Extensive structure activity relationship study was also carried out on these molecules. The physiochemical analysis, lipophilicity, solubility, pharmacokinetics and Lipinski drug likeness of nerolidol and its monosubstituted analogue was evaluated. The modification was done by substituting one of the methyl group (CH3) attachment of nerolidol with a COOH functional group. The scoring function (empirical binding free energy) and hydrogen bond formation was used to estimate the inhibitory effect of the protein-ligand complex. The binding energy of nerolidol was -5.9kcal/mol while that of its COOH analogue was -6.1Kcal/mol. The low free binding energy value (more negative value) displayed by the COOH analogue means it show a better activity than nerolidol. The two ligands showed the ability to cross the blood brain barrier (BBB). This also shows that they are both neuroactive. This result indicated that the COOH analogue may be better antiparasitic agent than nerolidol. Synthesis and preclinical studies of this monosubstituted derivative against the Trypanosoma brucei hexokinase is therefore recommended in order to confirm its potential as a better antiparasitic agent.

Description

Citation

1. Deborggraeve S, Koffi M, Jamonneau V, Bonsu FA, Queyson R, Simarro PP, Herdewijn P, Büscher P (August 2008). "Molecular analysis of archived blood slides reveals an atypical human Trypanosoma infection". Diagnostic Microbiology and Infectious Disease. 61 (4): 428–33. doi:10.1016/j.diagmicrobio.2008.03.006. PMID 18455900 2. WHO. "Trypanosomiasis, Human African (sleeping sickness)". Fact sheet N°259.World Health Organization.Retrieved 25 February 2014. 3. Maya JD, Cassels BK, Iturriaga-Vásquez P, et al. (2007). "Mode of action of natural and synthetic drugs against Trypanosomacruzi and their interaction with the mammalian host". Comp. Biochem. Physiol., Part a Mol. Integr. Physiol. 146 (4): 601–20. doi:10.1016/j.cbpa.2006.03.004. PMID 16626984 4. Baker JR (March 1995). "The subspecific taxonomy of Trypanosomabrucei".Parasite. 2(1): 3– 12. doi:10.1051/parasite/1995021003. PMID 9137639 5. Masocha W, Kristensson K (2012). "Passage of parasites across the blood-brain barrier".Virulence. 3 (2): 202–12. doi:10.4161/viru.19178. PMC 3396699. PMID 22460639

Collections

Endorsement

Review

Supplemented By

Referenced By